Concepedia

Alex Hoyle

AH

Statistics

Publications

15

Citations

2.5K

H-Index

13

Active since

2018

Affiliations

University College London(Current)

MRC Clinical Trials Unit at UCL

Institute of Cancer Research

University of Manchester

Cancer Research UK Manchester Institute

Alex Hoyle is an author at University College London specializing in oncology, medicine, and prostate cancer.

Publications per year

2018–2023

15

Publications

15

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker, Nicholas D. James, Chris Brawley et al. · The Lancet · 2018 · 1.3K citations · Full text

, , +13

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

N.W. Clarke, Amin Ali, Fiona C. Ingleby et al. · Annals of Oncology · 2019 · 398 citations · Full text

, , +17

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Alex Hoyle, Adnan Ali, Nicholas D. James et al. · European Urology · 2019 · 205 citations · Full text

, , +12

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer

Adnan Ali, Alex Hoyle, Áine Haran et al. · JAMA Oncology · 2021 · 137 citations · Full text

, , +17

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Chris Parker, Nicholas D. James, Chris Brawley et al. · PLoS Medicine · 2022 · 121 citations · Full text

, , +17

1–5 of 15